NEW YORK–(BUSINESS WIRE)–Kramer Levin is pleased to announce the promotion of Tristan Bonneau, Elan Daniels, Allison…
Año: 2023
Climate Vault Announces Recipients of Carbon Champion Awards
New award program recognizes forward-thinking organizations that leverage Climate Vault’s solutions as part of a holistic…
MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study
Pelabresib and ruxolitinib combination significantly reduced spleen size, with an SVR35 response rate nearly double that…
Latest Data of InnoCare’s Oncology Pipelines Presented at the 65th Annual Meeting of ASH
BEIJING–(BUSINESS WIRE)–InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of…
New Data for Genentech’s Columvi and Lunsumio Presented at ASH 2023 Support Continued Benefit for People With Lymphoma
– Longer-term data from pivotal studies of fixed-duration Columvi and Lunsumio continue to show durable responses…
ADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival at 12 months in Phase 2 Trial of Patients with Early Stage Classical Hodgkin Lymphoma
– 88% of patients with advanced stage classical Hodgkin Lymphoma in trial remained progression free at…
Belgian, Port Houston and Partners Sign Memorandum of Understanding on Energy Transition Cooperation
HOUSTON–(BUSINESS WIRE)–Today, H.E. Alexander De Croo, Prime Minister of Belgium, witnessed the signing of a Memorandum…
Marstacimab Phase 3 Data Presented at ASH 2023 Demonstrate Significant Bleed Reduction in Hemophilia A and B
Marstacimab reduced annualized bleeding rate by 35% and 92% compared to routine prophylaxis and on-demand treatment…
Orca Bio Presents Positive Data Demonstrating the Potential for Orca-T and Orca-Q to Expand Treatment to Additional Patient Groups at the 65th ASH Annual Meeting
– Orca-T, Orca Bio’s lead investigational high-precision cell therapy, showed similar results in older patients undergoing…
Bristol Myers Squibb Presents Primary Efficacy and Safety Analysis of the Phase 3 COMMANDS Trial of Reblozyl for Treatment of Anemia in Erythropoiesis Stimulating Agent-Naïve Patients with Lower-Risk Myelodysplastic Syndromes at ASH 2023
New data confirm findings consistent with interim analysis, reaffirming superior efficacy and significantly longer durability of…